65.49
前日終値:
$65.42
開ける:
$65.35
24時間の取引高:
361.41K
Relative Volume:
0.15
時価総額:
$10.44B
収益:
$705.14M
当期純損益:
$-453.90M
株価収益率:
-21.54
EPS:
-3.04
ネットキャッシュフロー:
$-551.29M
1週間 パフォーマンス:
+2.56%
1か月 パフォーマンス:
+53.81%
6か月 パフォーマンス:
+140.56%
1年 パフォーマンス:
+67.84%
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
IONS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
IONS
Ionis Pharmaceuticals Inc
|
65.50 | 10.43B | 705.14M | -453.90M | -551.29M | -3.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
403.99 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
608.50 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
459.88 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
768.60 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
343.08 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-09-26 | アップグレード | Goldman | Sell → Neutral |
2025-09-03 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2025-07-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2025-07-01 | アップグレード | Barclays | Equal Weight → Overweight |
2025-04-07 | 開始されました | H.C. Wainwright | Buy |
2025-03-31 | 開始されました | Redburn Atlantic | Neutral |
2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-07-16 | 再開されました | Jefferies | Buy |
2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
2023-09-29 | 開始されました | Raymond James | Strong Buy |
2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
2023-06-07 | 再開されました | Piper Sandler | Overweight |
2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
2023-03-21 | 開始されました | Bernstein | Underperform |
2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-09-09 | 再開されました | Morgan Stanley | Overweight |
2022-07-18 | 再開されました | Oppenheimer | Outperform |
2022-03-31 | 再開されました | Piper Sandler | Overweight |
2022-03-01 | 開始されました | Citigroup | Sell |
2022-03-01 | 開始されました | Guggenheim | Buy |
2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
2021-05-07 | アップグレード | UBS | Sell → Neutral |
2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
2020-12-16 | 開始されました | UBS | Sell |
2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
2020-09-14 | 再開されました | JP Morgan | Neutral |
2020-09-02 | 開始されました | The Benchmark Company | Hold |
2020-06-01 | 再開されました | Oppenheimer | Outperform |
2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
2020-03-05 | 開始されました | Citigroup | Buy |
2019-12-13 | 開始されました | Oppenheimer | Outperform |
2019-11-13 | 開始されました | BofA/Merrill | Buy |
2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
2018-08-08 | 繰り返されました | Stifel | Hold |
2018-08-07 | 繰り返されました | Stifel | Hold |
2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
2017-10-06 | 再開されました | Goldman | Sell |
2017-08-17 | 開始されました | Evercore ISI | Outperform |
2017-08-09 | 繰り返されました | Stifel | Hold |
2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
What analysts say about Ionis Pharmaceuticals Inc ISI stockDividend Stock Watch & High Return Wealth Plans - earlytimes.in
Ionis Pharmaceuticals stock hits 52-week high at 64.89 USD By Investing.com - Investing.com Canada
Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com
Is Ionis Pharmaceuticals Inc. (ISI) stock in buy zone after pullbackWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Investor Ratings Indicate Promising Upside Potential - DirectorsTalk Interviews
Published on: 2025-09-29 03:15:49 - newser.com
What drives Ionis Pharmaceuticals Inc stock priceVolume Weighted Average Price & Minimal Investment Profits - earlytimes.in
Assenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Should you hold or exit Ionis Pharmaceuticals Inc. nowQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com
Using fundamentals and technicals on Ionis Pharmaceuticals Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Ionis Pharmaceuticals (IONS) Is Up 5.0% After Positive Phase III Results for Alexander Disease Therapy - Yahoo Finance
IONS Upgraded by Goldman Sachs with a Significant Price Target I - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Neutral at The Goldman Sachs Group - MarketBeat
Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings - MarketBeat
Goldman Sachs Upgrades Ionis Pharmaceuticals to Neutral From Sell, Adjusts PT to $65 From $45 - MarketScreener
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals stock price target raised to $68 by Leerink Partners - Investing.com UK
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal - sharewise.com
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology - Nasdaq
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - Biogen
A Look at Ionis Pharmaceuticals’s Valuation as Zilganersen Delivers Breakthrough Results in Alexander Disease - Sahm
Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barron's
Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study - MedCity News
Barclays Maintains Overweight Rating on IONS, Raises Price Targe - GuruFocus
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease - Stocktwits
Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target P - GuruFocus
Guggenheim Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $83.00 at Bank of America - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease - BioSpace
IONS: HC Wainwright Reiterates Buy Rating with $95 Target | IONS Stock News - GuruFocus
Ionis reports positive results for Alexander disease drug zilganersen By Investing.com - Investing.com Nigeria
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease - BioSpace
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sovran Advisors LLC - MarketBeat
Ionis Targets Ultra-Rare Disease Market With Zilganersen - insights.citeline.com
Ionis reports positive results for Alexander disease drug zilganersen - Investing.com India
Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approval - Endpoints News
Ionis stock surges after positive results from Alexander disease drug By Investing.com - Investing.com Canada
Ionis reports promising data from study of Alexander disease therapy - Seeking Alpha
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial - Benzinga
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Ionis Pharmaceuticals (IONS) Reveals Promising Results for Zilga - GuruFocus
Ionis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease - Nasdaq
Ionis' brain disorder drug shows promise in clinical trial - TradingView
Applying big data sentiment scoring on Ionis Pharmaceuticals Inc.Weekly Stock Recap & Weekly Return Optimization Alerts - newser.com
Ionis and Sobi’s Tryngolza gains approval in EU for FCS treatment - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):